NPC1 as a Modulator of Disease Severity and Viral Entry of SARS-CoV-2

Date

2020

Type:

Article

item.page.extent

item.page.accessRights

item.contributor.advisor

ORCID:

Journal Title

Journal ISSN

Volume Title

Publisher

item.page.isbn

item.page.issn

item.page.issne

item.page.doiurl

item.page.other

item.page.references

Abstract

The COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1, MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic variants in NPC1, which encodes for the endo-lysosomal Niemann-Pick type C1 protein, restricts the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be explored.

Description

item.page.coverage.spatial

item.page.sponsorship

Citation

Current Molecular Medicine, 2020, 20: 1-3

Keywords

COVID-19, SARS-Cov-2, Niemann-Pick C1, Modifier gene, Drug repurposing, Virus, Infection

item.page.dc.rights

item.page.dc.rights.url